You are here

A Systematic Review of Delirium Biomarkers and Their Alignment with the NIA-AA Research Framework.

TitleA Systematic Review of Delirium Biomarkers and Their Alignment with the NIA-AA Research Framework.
Publication TypeJournal Article
Year of Publication2021
AuthorsWang S, Lindroth H, Chan C, Greene R, Serrano-Andrews P, Khan S, Rios G, Jabbari S, Lim J, Saykin AJ, Khan B
JournalJ Am Geriatr Soc
Volume69
Issue1
Pagination255-263
Date Published2021 01
ISSN1532-5415
KeywordsAmyloid beta-Peptides, Biomarkers, Delirium, Humans, National Institute on Aging (U.S.), Research, tau Proteins, United States
Abstract

OBJECTIVES: To identify whether delirium biomarkers aligned with the National Institute on Aging-Alzheimer's Association (NIA-AA) research framework, a conceptual model that describes the use of diagnostic biomarkers for Alzheimer's disease and other related dementias (ADRD).
DESIGN: Systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
SETTING: Acute care and outpatient settings.
PARTICIPANTS: Adults diagnosed with delirium.
METHODS AND MEASUREMENTS: MEDLINE, PsycInfo, Embase, and the Cochrane Library were searched for English-language studies published from January 2010 to February 2020. Studies included adults older than 18 years, identified delirium with a standardized assessment tool, and measured an ADRD biomarker. Independent reviewers determined whether an association between delirium and ADRD biomarker was found, the quality of biomarker data based on the REMARK (REporting recommendations for tumor MARKer prognostic studies) checklist, and the study bias based on the Newcastle-Ottawa Scale.
RESULTS: A total of 61,256 citations were identified; 113 studies were included. Most studies did not examine amyloid, tau, or neurodegeneration biomarkers. Delirium may be associated with neurodegeneration biomarkers, but few to no studies found an association with amyloid and tau biomarkers. Delirium was not consistently associated with inflammatory biomarkers. The quality of biomarker data was moderate, and the risk of bias was moderate to high. Studies often did not collect prehospital and posthospital cognitive data.
CONCLUSION: Most delirium diagnostic biomarker studies did not measure amyloid, tau, and/or neurodegenerative biomarkers, making characterization of the relationship between delirium and ADRD difficult. Future delirium biomarker diagnostic studies could improve the understanding of pathophysiologic links between delirium with other conditions affecting cognition.

DOI10.1111/jgs.16836
Pubmed Linkhttps://www.ncbi.nlm.nih.gov/pubmed/32975827?dopt=Abstract
page_expoInternal
Alternate JournalJ Am Geriatr Soc
PubMed ID32975827
PubMed Central IDPMC7923964
Grant List5T32HL091816 / HL / NHLBI NIH HHS / United States
R01 AG019771 / AG / NIA NIH HHS / United States
U01 AG068057 / AG / NIA NIH HHS / United States
K23 AG062555 / AG / NIA NIH HHS / United States
CA129769 / NH / NIH HHS / United States
R01 CA129769 / CA / NCI NIH HHS / United States
R01 HL131730 / HL / NHLBI NIH HHS / United States
R01 AG067631 / AG / NIA NIH HHS / United States
K23AG062555 / AG / NIA NIH HHS / United States
P30 AG010133 / AG / NIA NIH HHS / United States
2P30AG010133 / AG / NIA NIH HHS / United States
R01HL131730 / HL / NHLBI NIH HHS / United States
T32 HL091816 / HL / NHLBI NIH HHS / United States
R01AG055391 / AG / NIA NIH HHS / United States
R01 AG055391 / AG / NIA NIH HHS / United States

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer